Thursday, August 20

The Treasury doubled long-dated buybacks to at least $4 billion per operation, up from $2 billion, in the two months before the midterm elections. The announcement sparked a bond rally and initially weakened the dollar, offering a technical liquidity backstop to a market strained by persistent selling at the long end.

The relief was limited. The 10-year yield remained near 4.74% and the 30-year around 5.27%, leaving long rates near decade-plus highs. The intervention therefore looks more effective at improving market functioning than at changing the underlying rate regime. The Federal Reserve’s July minutes, with a 9-3 decision to hold rates at 3.50%-3.75% and several officials still concerned about inflation, reinforce why Treasury support is not equivalent to monetary easing. Friday’s equity rebound did little to alter that cross-asset signal.

Oil rose more than 2% Thursday after President Trump threatened retaliation against countries supporting Iran, with Brent settling at its highest level in nearly a month and remaining above $93.50 on Friday. Treasury Secretary Scott Bessent’s pledge of the “toughest sanctions in history” on Iran added a policy channel to the supply risk.

The UAE’s halt to financial and economic transactions with Iran, after accusing Tehran of ballistic-missile attacks, underscored that diplomatic and sanctions pressure is intensifying rather than fading. Market concern also centers on the Strait of Hormuz, making crude the immediate transmission mechanism from geopolitics to inflation expectations, sovereign yields and equity risk premia. The rebound in U.S. stocks—up 0.98% for the Dow and 0.43% for the S&P 500—therefore reads as a relief move vulnerable to another energy shock.

Moderna surged 177% after results from a cancer-vaccine trial generated strong market enthusiasm, making the company the standout single-stock event in the window. The move was large enough to lift healthcare relative to other sectors and illustrates how clinical data can overwhelm the broader market’s rates-driven risk backdrop.

The contrast with technology was notable: the freshest sector-specific development was not an AI or semiconductor catalyst, but a biotech rerating. Starlink’s renewed application for approval in India supplied a separate regulatory signal for satellite expansion, though it lacked Moderna’s immediate market impact. With the Nasdaq still down 2.05% for the week despite Friday’s 0.44% gain, the episode highlighted the widening gap between index-level sensitivity to yields and stock-specific upside from material company news.